FTRE MEXC RealStocks
Own real FTRE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 06:48:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Fortrea Holdings Inc. (FTRE) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $20.53, with a market capitalization of $1.89B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8.55 to $26.16. This page covers its latest market performance, valuation, price trends and company information.
$1.89B | |
$19.52 | |
$20.56 | |
$19.25 | |
$19.59 | |
1.01M | |
1.68M | |
-- | |
$26.16 | |
$8.55 | |
-- | |
2026-09-30 |
Fortrea Holdings Inc. (FTRE) last closed at $20.53 as of 2026-11-19 00:31:00, up 4.70% ($0.92) from the previous close of $19.59.
During the latest regular trading session, FTRE traded between $19.25 and $20.56, with a volume of 1.01M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Fortrea Holdings Inc. (FTRE) moved from $21.39 to $20.53, representing a decline of 4.01% ($0.86).
The stock traded between $18.97 and $22.04 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.61 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 68.0%
FTRE is currently trading at $20.53, placing it 68.0% of the way from its 52-week low of $8.55 to its 52-week high of $26.16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 14,000 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fortrea Holdings Inc. (FTRE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to FTRE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between FTRE shares and USD.
FTRE Shares to USD
1.00 FTRE shares = 20.532 USD
Calculations are estimates based on the latest available price and are for reference only.